Are You in Control of Your Data

Seeplex® Diarrhea-V ACE Detection Test Receives Health Canada Licence

Seegene, Inc., has received a Medical Device License from Health Canada for its Seeplex® Diarrhea-V ACE Detection test. Built on the novel and proprietary Seeplex® molecular diagnostic platform that delivers maximum specificity, reproducibility and sensitivity, the Canadian healthcare system can now use the Seegene viral diarrhea detection kit to further improve patient care and reduce healthcare costs.

Already permitted for use in more than 30 countries recognizing the CE Mark, the license from Health Canada will bring the Diarrhea-V ACE Detection test to North America for the first time.

The Seeplex® Diarrhea-V ACE Detection is a qualitative in vitro test that responds to an unmet clinical need for rapid detection and diagnosis of a range of viral pathogens including enteric adenovirus (AdV), Group A rotavirus (RotV), Norovirus GI (NoV-G1) / GII (NoV-G2), Astrovirus (AstV).

The traditional methods for diagnosis of diarrhea are microscopy, ELISA, and stool culture, which have notable performance limitations that include a lack of both sensitivity and specificity, ease of use, and rapid turn-around for results. Applying a proprietary PCR technology, the Seeplex® Diarrhea-V ACE Detection is a multiplex assay that permits the simultaneous amplification of target pathogens and provides a clear break from established procedures with accurate, rapid and cost-effective diarrhea diagnostics.

'In this era of viral epidemics clinicians require the ability to routinely test for a wide spectrum of pathogens in a single test,' said Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene. 'The Seeplex Diarrhea-V test is uniquely performed with one multiplex PCR in a single tube and capillary electrophoresis for automated detection of pathogens providing a new standard for test reproducibility, specificity and sensitivity.'



NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source: Seegene Inc. View latest company information

Posted: January 12, 2010
Request Information
[will open your email client]

© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed